ClinicalTrials.gg
CompletedNCT03474523Updated Mar 13, 2020

Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment

An interventional study of Experimental group and Control group in Cellulitis, sponsored by University of Cadiz. Completed at 1 site in Spain. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-13.

Sponsored by University of Cadiz · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2017, registered Feb 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The aim of the present study is to value the effectiveness of Diathermy-Radiofrecuency treatment compared to Cavitation treatment in woman with cellulitis.

Read the detailed description

The edemato-fibrosclerotic panniculopathy is a segmental disease and lipodystrophy, this disease is localized in subcutaneous connective tissue which is influenced by venous and lymphatic system, when these systems are affected. The secondary vasomotor dysfunction to failure sympathetic nervous system influence on this disease too.

Usually it affects women, influencing their physical and psychological well-being.

The Aesthetic Physiotherapy, known as Aesthetics Plastic and Restorative Physiotherapy, is in their beginnings, there are little studies which present this pathology from the physiotherapy perspective. The investigators believe that their research could make some progress in this matter.

The search found very few clinical trials of scientific rigor about radio frequency and cavitation, and The investigators didn't find studies that compare both. Both treatments show effectiveness in improving the appearance of cellulite, so it would be a good idea compare them and see the most effective.

The investigators are trying to compare the effectiveness of both techniques and the investigators consider innovative and with added value to investigate something that we haven´t found in the reviewed literature.

The investigators choose 20 women randomly, 40 sample subjects, between 18-40 years old. These women must keep the inclusion criteria.

The participants attend a first date where the investigators collect the necessary data, and they are valued before and after the treatment (perimetry, photographic, Nürnberger and Müller scale, weight, height, BMI).

Then each patient receive treatment, seven non-consecutive sessions Diathermy-Radiofrequency on one leg (gluteal zone, internal and lateral zone, posterior and anterior zone) and other 7 sessions of Cavitation in the other leg, and Presotherapy in both legs.

The investigators also advice the participants about their diet and exercise.

02

Conditions studied

  • Cellulitis

Browse trials for

Keywords

  • radio frequency diathermy
  • cavitation
  • ultrasound
  • edemato-fibrosclerotic panniculopathy
  • cellulitis
03

In context

Cellulitis

160 studies on the registry are indexed under Cellulitis; 14 are open to participants now.

This study's enrollment of 40 is below the median of 157 across 124 interventional studies indexed under Cellulitis.

Browse Cellulitis studies →

Lead sponsor

University of Cadiz is the lead sponsor of 55 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • UCA comunity
  • Age 18-40 years
  • Cellulite grade I, II, III (Nürnberg\&Müller clasification)
  • Compliance of study timing
  • Acceptance of and signature of study authorization

Exclusion criteria

Exclusion Criteria:

  • Pacemaker, heart diseases, epilepsy,
  • pregnancy, lactation, last year postpartum, menstrual cycle alterations, climacteric, perimenopause
  • chronic disease, hormonal or circulatory disorder, neoplasia process
  • inflammation, infection, active acne, open wound in the treatment area
  • above 27 Kg/m2, obesity, lipoedema, oedema, circulatory problems
  • Metal implants, prosthesis, intrauterine devices
  • Evolutive diseases
  • Severe Artheryal hipertension
  • High cholesterol levels or non-controlled triglycerides
  • Weight fluctuation above 2 kg in the last six months
  • Drinking more than two daily alcoholic drinks
  • Pharmacological treatment during study: anti-inflammatory, esthetical, cosmetical or dietetic treatment
  • Previous treatment of the studies areas in the last year
  • Surgery intervention in studies areas
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Experimental or Diathermy-Radiofrecuency

    All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment

    Other: Experimental group

  • Active comparator
    Control or Cavitation

    All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment

    Other: Control group

Interventions

  • OtherExperimental group

    Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode. Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9

  • OtherControl group

    Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality. Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9

06

What researchers measure

Primary outcomes

  1. Decrease in perimeter measures

    measuring tape

    Time frame: At the begining and at the end of the treatment after seven weeks

Secondary outcomes

  1. Changes in body mass index

    Calculation of the body mass index

    Time frame: At the begining and at the end of the treatment after seven weeks

  2. Changes in weight

    Weighing machine

    Time frame: At the begining and at the end of the treatment after seven weeks

  3. Physical activity evaluation

    IPAQ questionnaire

    Time frame: At the begining and at the end of the treatment after seven weeks

  4. Degree of cellulitis

    Nürberger and Müller's scale

    Time frame: At the begining and at the end of the treatment after seven weeks. This scale measures the level of cellulite and takes the values of 0-3, being 0 the value where there is no cellulite and 3 the most serious stage of cellulite.

07

Study locations

1 site
  • Faculty of Nursing and Physiotherapy. University of Cadiz
    Cádiz, 11008, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Mar 2020, 28 months.

Of 18 interventional studies with no phase under Cellulitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2018
First posted
Mar 22, 2018
StartActual
Oct 20, 2017
Primary completionActual
Mar 11, 2020
CompletionActual
Mar 11, 2020
Last update
Mar 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03474523
Lead sponsor
University of Cadiz
Responsible party
Ines Carmona Barrientos (Principal Investigator, University of Cadiz) — Principal investigator
First posted
Mar 22, 2018
Start date
Oct 20, 2017
Primary completion
Mar 11, 2020
Completion
Mar 11, 2020
Last update
Mar 13, 2020

Study contacts

Carmona I. Barrientos, Dra
principal investigator · University of Cadiz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion